129 related articles for article (PubMed ID: 16520662)
1. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner I; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2006 Mar; 17(3):333-6. PubMed ID: 16520662
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
3. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
5. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
[TBL] [Abstract][Full Text] [Related]
7. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
8. Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.
Elie BT; Fernández-Gallardo J; Curado N; Cornejo MA; Ramos JW; Contel M
Eur J Med Chem; 2019 Jan; 161():310-322. PubMed ID: 30368130
[TBL] [Abstract][Full Text] [Related]
9. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
Köpf-Maier P
J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
[TBL] [Abstract][Full Text] [Related]
10. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
[TBL] [Abstract][Full Text] [Related]
12. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
13. Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.
Villena-Heinsen C; Friedrich M; Ertan AK; Farnhammer C; Schmidt W
Anticancer Drugs; 1998 Jul; 9(6):557-63. PubMed ID: 9877245
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
16. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
17. Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract.
Köpf-Maier P
Cancer Chemother Pharmacol; 1989; 23(4):225-30. PubMed ID: 2924380
[TBL] [Abstract][Full Text] [Related]
18. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
19. Dimethyl titanocene Y: a valuable precursor for libraries of cytotoxic titanocene derivatives.
Immel TA; Martin JT; Dürr CJ; Groth U; Huhn T
J Inorg Biochem; 2010 Aug; 104(8):863-7. PubMed ID: 20452674
[TBL] [Abstract][Full Text] [Related]
20. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
